CD274 and small cell lung carcinoma: In the IMpower133 trial, Horn and coworkers reported a substantial benefit by the addition of the PD-L1 blocker atezolizumab to chemotherapy in the first-line treatment of extensive-stage SCLC, which resulted in significantly longer overall survival and progression-free survival than chemotherapy alone [32].